美股
Lead report
Spero outlines cash runway into the second half of 2029 following $105M royalty financing (NASDAQ:SPRO)
Spero Therapeutics (SPRO) Q2 2026 earnings call highlights: FDA approval of Utebzi, SP001 licensing, $105M royalty financing, runway to 2029âread now.
